Topical nanoparticulate spironolactone formulation
AssigneeJagotec AG
InventorsGuy Vergnault, Pascal Grenier, Alain Nhamias, Dieter Scherer, Petra Beck, Patricia Cancade
Life of this patent
Estimating the term…
Abstract
The invention relates to a topical nanoparticulate spironolactone formulation comprising nanoparticles having a mean diameter, measured by a photon correlation spectroscopy, in the range of from about 300 nm to about 900 nm. The nanoparticles are incorporated into a crystalline network system comprising a dispersion of solid crystals of polar lipids, said lipids exposing their hydrophilic side outwards and their hydrophobic side inwards towards the spironolactone nanoparticles.
Claims24
A topical nanoparticulate spironolactone formulation comprising nanoparticles having a mean diameter, measured by photon correlation spectroscopy, in the range of from about 300 nm to about 900 nm, incorporated into a crystalline network system comprising a dispersion of solid crystals of polar lipids, said lipids exposing their hydrophilic side outwards and their hydrophobic side inwards toward the spironolactone nanoparticles.
(canceled)
The method according to claim 22, wherein the condition is selected from acne, hirsutism, androgenic alopecia, or rosacea.
The method according to claim 22, wherein the spironolactone nanosuspension is topically applied.
The method according to claim 22, wherein the nanoparticles are incorporated into a cream base.
A crystalline network system comprising a dispersion of solid crystals of polar lipids, said lipids having their hydrophilic side exposed outwards and their hydrophobic side inwards toward an incorporated substances, for use in the topical treatment of acne.
A process for the preparation of a topical nanoparticulate spironolactone formulation comprising nanoparticles having a mean diameter in the range of from about 300 nm to about 900 nm as measured by photon correlation spectroscopy, said process comprising:
- incorporating of a nanosuspension of spironolactone into an aqueous dispersion of solid crystals of polar lipids, said lipids having their hydrophilic side exposed outwards and their hydrophobic side inwards toward the spironolactone nanoparticles.
A method of treating a condition that responds to anti-androgens, comprising:
- administering a spironolactone nanosuspension comprising nanoparticles having a mean diameter in the range of from about 300 nm to about 900 nm, as measured by photon correlation spectroscopy, in an amount effective to treat the condition.
Dependencies are inferred from the claim text.